根除幽门螺杆菌患者中阿司匹林降低胃肠道癌症死亡与出血风险的获益与危害
研究基于全地区数据库观察2003至2016年间根除幽门螺杆菌患者至2020年7月,中位随访10.1年。阿司匹林与较低的胃肠道癌症相关死亡相关(aHR 0.51),但与较高的出血相关死亡相关(aHR 1.52);合并质子泵抑制剂(PPI)使用者出血相关死亡aHR为1.06。作者认为根除幽门螺杆菌者中阿司匹林的癌症死亡获益超过出血死亡风险,PPI使用进一步增强该获益。
要点
- 根除幽门螺杆菌者中,阿司匹林与胃肠道癌症死亡降低相关(aHR 0.51,95%CI 0.42-0.61)。
- 阿司匹林与出血相关死亡升高相关(aHR 1.52,95%CI 1.11-2.08),合并PPI使用者aHR为1.06(95%CI 0.70-1.63)。
- 全队列每万人年癌症相关死亡减少7例(95%CI 5-8),出血相关死亡增加1例(95%CI 0.3-3)。
核心结论
- 根除幽门螺杆菌者中,阿司匹林降低胃肠道癌症死亡的获益超过出血相关死亡风险,合并PPI使用进一步增强该获益。
研究设计与样本
- 研究为观察性队列,对象为2003至2016年间根除幽门螺杆菌的患者,来自全地区数据库,自幽门螺杆菌治疗日起随访至死亡或研究结束(2020年7月)。
- 共纳入87967名受试者,中位随访10.1年。
- 主要暴露为阿司匹林使用(作为时变变量);主要结局为胃肠道癌症相关死亡(胃肠道、肝胆或胰腺癌),次要结局为出血相关死亡(胃肠道出血或颅内出血)。
主要发现
- 随访期间发生1294例(1.5%)胃肠道癌症相关死亡和304例(0.3%)出血相关死亡。
- 阿司匹林与较低的胃肠道癌症相关死亡相关(aHR 0.51,95%CI 0.42-0.61),与较高的出血相关死亡相关(aHR 1.52,95%CI 1.11-2.08)。
- 合并PPI使用者中,阿司匹林相关的出血相关死亡aHR为1.06(95%CI 0.70-1.63)。
- 全队列中,阿司匹林使用者与非使用者相比,调整后绝对风险差为每万人年癌症相关死亡减少7例(95%CI 5-8)、出血相关死亡增加1例(95%CI 0.3-3)。
- 合并PPI与阿司匹林使用者中,每万人年癌症相关死亡减少9例(95%CI 8-10),出血相关死亡未增加。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND & AIMS: We investigated the benefit-risk profile of aspirin on mortality reduction from chemoprevention of gastrointestinal (GI) cancer vs excess mortality from bleeding among Helicobacter pylori-eradicated patients, and its interaction with proton pump inhibitors (PPIs). METHODS: H pylori-eradicated patients (between 2003 and 2016), identified from a territory-wide database, were observed from the date of H pylori therapy until death or the end of the study (July 2020). Primary exposure was aspirin use as time-varying variable. The primary outcome was GI cancer-related (gastrointestinal, hepatobiliary, or pancreatic cancer) death and the secondary outcome was bleeding-related (gastrointestinal bleeding or intracranial bleeding) death. The adjusted hazard ratio (aHR) of outcomes was calculated by multivariable Cox model after adjusting for age, sex, comorbidities, and concomitant medications. The benefit-risk profile was expressed as the adjusted absolute risk difference of cancer-related deaths and bleeding-related deaths between aspirin users and nonusers. RESULTS: A total of 87,967 subjects were followed up for a median of 10.1 years, with 1294 (1.5%) GI cancer-related deaths and 304 (0.3%) bleeding-related deaths. Aspirin was associated with lower GI cancer-related mortality (aHR, 0.51; 95% CI, 0.42-0.61), but higher bleeding-related mortality (aHR, 1.52; 95% CI, 1.11-2.08). Among PPI users, the aHR of bleeding-related mortality with aspirin was 1.06 (95% CI, 0.70-1.63). For the whole cohort, the adjusted absolute risk difference between aspirin users and nonusers was 7 (95% CI, 5-8) fewer cancer-related and 1 (95% CI, 0.3-3) more bleeding-related death per 10,000 person-years. Among concomitant PPI-aspirin use, there were 9 (95% CI, 8-10) fewer cancer-related deaths per 10,000 person-years without an increase in bleeding-related deaths. CONCLUSIONS: GI cancer mortality benefit from aspirin outweighs bleeding-related mortality in H pylori-eradicated subjects, which is enhanced further by PPI use.
引用
- Cheung KS, Li B, Wong IY, et al. Benefit and Harm of Aspirin on Mortality From Gastrointestinal Cancers Vs Bleeding in Helicobacter pylori-Eradicated Patients. Clin Gastroenterol Hepatol. 2024. PMID: 38750871. doi:10.1016/j.cgh.2024.05.003
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。